BRAF and neoplasm: In a nude mouse subcutaneous tumor model, concurrent treatment with C225 and 4D3 resulted in more effective inhibition of tumor growth than C225 alone in both Caco-2 (ras wild type) and HT29 (ras wild type, Braf mutant) cells (Figure 5D, 5E), both of which are reported to respond to C225 [20].